Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 1999, p. 2081-2083, Vol. 43, No. 8
Department of Chemistry, Bose Institute,
Calcutta 700 009, India
Received 16 November 1998/Returned for modification 3 March
1999/Accepted 6 June 1999
A Shigella species are a
major cause of diarrheal diseases and mortality in developing countries
(4), and the frequency of strains multiply resistant to
ampicillin, trimethoprim-sulfamethoxazole, and streptomycin is
causing growing concern. Bacteria were routinely grown in tryptic soy broth on a rotary shaker
at 37°C. The Hydrolysis of Conjugative transfer of S. dysenteriae PB-10 antibiotic
resistance plasmid into Escherichia coli HB-101 was
performed as described previously by Philippon et al. (18).
Transconjugants were selected by plating on medium containing 25 µg
of ampicillin/ml and 10 µg of rifampin/ml.
For cloning of the The
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Molecular Characterization of the SHV-11
-Lactamase of Shigella dysenteriae
![]()
ABSTRACT
Top
Abstract
Text
References
-lactamase with an Mr of 29,000 and a
pI of 7.6 was partially purified from a clinical isolate of
Shigella dysenteriae. The bla gene encoded the
SHV-11 enzyme carrying the substitution Leu
Gln at position 35 and
was linked to a strong promoter. This variant, unlike the prototype
SHV-1 enzyme, hydrolyzed oxacillin, cloxacillin, and
oxyiminocephalosporins such as cefotaxime.
![]()
TEXT
Top
Abstract
Text
References
-Lactamases are primarily responsible for
-lactam resistance in gram-negative bacteria. The presence of TEM-,
OXA-1, and OXA-3
-lactamases in S. flexneri and S. sonnei has been previously reported (21). However,
detailed characterization of these enzymes in S. dysenteriae is lacking. We report a clinical strain of S. dysenteriae
PB-10 (obtained from the National Institute of Cholera and Enteric
Diseases [NICED], Calcutta, India) harboring the SHV-11
-lactamase
capable of hydrolyzing oxacillin, cloxcillin, and oxyimnocephalosporins.
-lactamase was partially purified from sonic extracts
of cells by size-exclusion chromatography on Sephadex G-75, followed by
successive chromatography on a Q-Sepharose anion exchanger at pH 7 (at
which time
-lactamase activity remained in the flowthrough) and then
at pH 10 (where
-lactamase activity eluted at a salt concentration
of 0.1 M NaCl in 20 mM ethanolamine containing 5% glycerol and 5%
ethylene glycol). During purification of the enzyme,
-lactamase
activity was routinely determined at 30°C by monitoring the
hydrolysis of nitrocefin spectrophotometrically at 482 nm
(17). One unit of
-lactamase activity is the amount of
enzyme hydrolyzing 1 µmol of nitrocefin per min.
-lactams was monitored at 30°C in 100 mM sodium
phosphate buffer, pH 7.2, at wavelengths that gave a maximum in the
difference spectrum of the hydrolyzed antibiotic against the
unhydrolyzed antibiotic. The relative Vmax
values of the substrates were obtained after absorbance data were fit
to the integrated Michaelis-Menten equation (7). The rate of
hydrolysis of benzylpenicillin was set at 100.
-lactamase gene, plasmid DNA from the
transconjugant was partially digested with BamHI and ligated
to the BamHI-digested vector pK19 (20).
Transformants were selected on Luria-Bertani agar supplemented with 1 mM isopropyl-
-D-thiogalactopyranoside (IPTG), 50 µg of
ampicillin, and 50 µg of kanamycin per ml. Plasmid DNA containing an
9-kb insert was subsequently subcloned in several steps by using
successively the enzymes SstI, SaII, and
AvaI and selecting each time for Amp Kanr
recombinants. The plasmid obtained in the final step, pMK105, contained
a 1.8-kb insert. A library of nested deletions of the clone pMK105 was
finally generated in the vector pK19 to sequence the entire cloned DNA,
by using the double-stranded nested deletion kit from Amersham
Pharmacia Biotech. DNA sequencing was done by using the Thermosequenase
cycle sequencing kit (Amersham Pharmacia Biotech). Both strands of DNA
were sequenced from two clones. The nucleotide sequence and the deduced
protein sequence were analyzed by using the Genetics Computer Group
software package. Similarity searches were performed by using the Gap
BLAST algorithm (1).
-lactam resistance of strain PB10 could be transferred to a
rifampin-resistant strain of E. coli, HB101, by
transconjugation. MICs were determined on Mueller-Hinton agar plates
containing serial dilutions of antibiotics by inoculating with
104 CFU per spot and reading after 18 h of growth at
37°C. The clinical isolate PB-10 was resistant toward all the
penicillins and some of the cephalosporins tested (Table
1). Cefoxitin and imipenem appeared to be
the most effective antibiotics. The MICs of selected antibiotics were
determined in combination with that of clavulanic acid (MIC, 32 µg/ml) at a concentration of 4 µg/ml. The decreased MICs indicated
the involvement of a transferable
-lactamase resistant to strain
PB-10. The cefotaxime and ceftazidime MICs are high compared to data
reported earlier for Shigella species (6, 21).
For cefotaxime, this could be due, at least in part, to the presence of
the
-lactamase reported here, since a decrease in the MIC was
observed in the presence of clavulanic acid for strain PB-10. The
higher ceftazidime MIC could not be correlated with
-lactamase
activity, particularly since there was no decrease in the MIC in the
presence of clavulanate.
TABLE 1.
In vitro susceptibilities of S. dysenteriae
and transconjugant to
-lactam antibiotics
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the cell
lysate and the partially purified
-lactamase of strain PB-10,
followed by renaturation and overlay of gels with nitrocefin (12), showed the presence of a single band of
-lactamase
activity, with an approximate Mr of 29,000 ± 2,000 (mean ± standard deviation). Isoelectric focusing of the
reference SHV-1 enzyme as well (3) as crude and partially
purified
-lactamase of PB-10, followed by overlay with nitrocefin,
showed in each case a single band with
-lactamase activity at an
isoelectric point of 7.6 ± 0.2, which corresponded to that
reported for SHV enzymes (2, 5).
The hydrolysis of cephaloridine and of almost all other cephalosporins
tested was much slower than that of benzylpenicillin, nitrocefin being
the only exception (Table 2). The
oxyiminocephalosporins cefotaxime, cefuroxime, and ceftizoxime were
hydrolyzed at measurable rates. No detectable hydrolytic activity was
observed for ceftazidime, cefoxitin, cefsulodin, aztreonam, or
imipenem. Also, these antibiotics failed to inhibit the enzyme. Unlike
other SHV enzymes, the PB-10 enzyme hydrolyzed oxacillin and
cloxacillin at appreciable rates. Comparison of relative rates of
hydrolysis of
-lactams by a reference SHV-1 enzyme and the
-lactamase harbored by pMK105 demonstrate that, unlike the reference
SHV-1 enzyme, the
-lactamase produced by pMK105 hydrolyzed
oxacillin. Cefotaxime was hydrolyzed by this enzyme, whereas its
hydrolysis could not be measured with the reference SHV-1 enzyme.
Sensitivity to clavulanic acid is characteristic of TEM and SHV
enzymes. The 50% inhibitory concentrations (IC50) of
clavulanic acid and sulbactam were determined by incubating the enzyme
with either inhibitor for 10 min prior to the addition of
benzylpenicillin (1 mM). The IC50 was determined
graphically. For clavulanic acid, the values were 2 and 40 nM, while
for sulbactam, the values were 17,000 and 30,000 nM for the reference
strain SHV-1 and the S. dysenteriae enzyme, respectively.
The S. dysenteriae enzyme was therefore less susceptible to
clavulanic acid and sulbactam than the SHV-1 enzyme.
|
The nucleotide sequence (EMBL nucleotide sequence database, accession
no. Y18299) of the plasmid pMK105 revealed a 286-amino-acid open
reading frame. The nucleotide sequence corresponding to positions 1 through 286 of the deduced amino acid sequence was identical to that
reported for the Klebsiella pneumoniae SHV-1a (or SHV-11) (GenBank accession no. X98101), except for a silent CAC-to-CAT mutation
encoding histidine 108. Mutations of the plasmid-determined TEM, SHV,
and OXA
-lactamases that enhance their affinity for expanded-spectrum cephalosporins usually occur between positions 104 and 240. These mutations have resulted in roomier active-site cavities
that permit expanded-spectrum
-lactams with bulky side chains to
enter and bind to the active site serine-70 (10, 13). With
site-directed mutants it has been reported that the leu
gln substitution at position 35 on the protruding NH2 terminus
(16) increases resistance to ceftazidime but reduces the
MICs of all other cephalosporins tested compared to SHV-2. In our case,
the situation was not comparable, since the SHV-11 enzyme has glycine at position 238 rather than serine, as in SHV-2. (8) A
survey of SHV
-lactamases in Switzerland previously led to the
identification of the variant enzyme SHV-11 (15) harboring
the Leu
Gln substitution at position 35. In this report, K. pneumoniae KPZU-12, harboring the SHV-11
-lactamase, showed
-lactam susceptibilities virtually identical to K. pneumoniae KPAA-I harboring the SHV-1
-lactamase. We
demonstrate that the SHV-11 enzyme from S. dysenteriae
hydrolyzes oxyiminocephalosporins. The hydrolysis of oxacillin and
cloxacillin was intriguing.
There was little similarity of the nucleotide sequence upstream of the
10 with that of the prototype SHV-1 bla gene
(14). Changes in the
35 and
10 regions are a powerful
influence on promoter strength (11). In E. coli,
the closer the sequence is to the consensus, the stronger the promoter
(
35 consensus sequence, TTGACA;
10 consensus sequence,
TATAAT) (9). The promoter comprising
5'TTGCAA'3' (
35 box) and 5'TATTCT3' (
10 box)
identified in the pMK105 bla gene has been reported to
increase
-lactam resistance when coupled to the SHV-2 gene.
(19). The association of the bla gene with a
strong promoter likely influenced susceptibilities to
-lactams in
the present study as well.
The continued emergence of
-lactam-resistant S. dysenteriae is of particular concern to developing countries.
Surprisingly, reports of noteworthy efforts to characterize the
-lactamases most likely to be associated with this resistance
phenomenon are sparse in the literature, particularly in terms of
nucleotide sequence information. Our report describes perhaps the first
serious attempt both to characterize the structural bla gene
of a
-lactamase from a clinical isolate of S. dysenteriae
and to biochemically characterize the elaborated enzyme. Although the
leu-35
gln substitution had been reported while this work was in
progress (15), its effect on substrate profile had not been
investigated. Rather, conclusions had been drawn merely from an
evaluation of MIC data, which may be influenced by an interplay of
factors, including the permeability of the outer membrane of the hosts,
the amount of
-lactamase produced, the affinities of the target
penicillin-binding proteins for the tested
-lactam, and the
involvement of efflux pumps. We demonstrate, using the SHV-1 J35R1010
as a reference enzyme, that the SHV-11 enzyme hydrolyzes oxacillin,
cloxacillin, and oxyiminocephalosporins such as cefotaxime and is less
sensitive to clavulanic acid. The results from our biochemical
characterization of this enzyme suggest that an amino acid substitution
in the protruding amino terminus of the
-lactamase likely alters the overall conformation of the molecule and, consequently, its substrate profile. The structural basis for this needs to be investigated further.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by grants from the Department of Science and Technology and the Council of Scientific and Industrial Research, government of India.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Chemistry, Bose Institute, 93/1 Acharya Prafulla Chandra Rd., Calcutta 700 009, India. Phone: 91 33 350 6619. Fax: 91 33 3506790. E-mail: mani{at}boseinst.ernet.in.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Altschul, S. F.,
T. L. Madden,
A. A. Schäffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 2. |
Ambler, R. P.,
F. W. Coulson,
J.-M. Frere,
J.-M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-270.
|
| 3. |
Barthelemy, M.,
J. Peduzzi, and R. Labia.
1988.
Complete amino acid sequence of p453-plasmid-mediated PIT-2 -lactamase (SHV-1)
Biochem. J.
251:73-79[Medline].
|
| 4. |
Bennish, M. L., and M. A. Salam.
1992.
Rethinking options of the treatment of shigellosis.
J. Antimicrob. Chemother.
30:243-247 |
| 5. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamase and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 6. | Cavallo, J. D., J. Bericon, J. M. Bandet, T. Samson, M. France, and M. Meyran. 1993. Antibiotic sensitivity of 140 strains of Shigella isolated in Djibouti. Bull. Soc. Pathol. Exot. 86:35-40[Medline]. |
| 7. | De Meester, F., B. Joris, G. Reckinger, C. Bellefroid-Bourguignon, J. M. Frere, and S. G. Waley. 1987. Automated analysis of enzyme inactivation phenomena. Biochem. Pharmacol. 36:2393-2403[Medline]. |
| 8. |
Garbarg-Chenon, A.,
V. Godard,
R. Labia, and J.-C. Nicolas.
1990.
Nucleotide sequence of SHV-2 -lactamase gene.
Antimicrob. Agents Chemother.
34:1444-1446 |
| 9. |
Hawley, D., and W. R. McClure.
1983.
Compilation and analysis of Escherichia coli promoter DNA sequences.
Nucleic Acids Res.
11:2237-2255 |
| 10. |
Herzberg, O., and J. Moult.
1987.
Bacterial resistance to -lactam antibiotics: crystal structure of -lactamase from Staphylococcus aureus PC1 at 2.5 A resolution.
Science
236:694-701 |
| 11. |
Kobayashi, M.,
K. Nagata, and A. Ishihama.
1990.
Promoter selectivity of Escherichia coli RNA polymerase: effect of base substitutions in the promoter-35 region on promoter strength.
Nucleic Acids Res.
18:7367-7372 |
| 12. |
Matthew, M.,
A. M. Harris,
M. J. Marshall, and G. W. Ross.
1975.
The use of analytical isoelectric focusing for detection and identification of -lactamase.
J. Gen. Microbiol.
88:169-178[Medline].
|
| 13. |
Medeiros, A. A.
1997.
Evolution and dissemination of -lactamases accelerated by generations of -lactam antibiotics.
Clin. Infect. Dis.
24:S19-S45.
|
| 14. |
Mercier, J., and R. C. Levesque.
1990.
Cloning of SHV-2, OHIO-1, and OXA-6 -lactamases and cloning and sequencing of SHV-1 -lactamase.
Antimicrob. Agents Chemother.
34:1577-1583 |
| 15. |
Nüesch-Inderbinen, M. T.,
F. H. Kayser, and H. Hächler.
1997.
Survey and molecular genetics of SHV -lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12.
Antimicrob. Agents Chemother.
41:943-949[Abstract].
|
| 16. |
Nüesch-Inderbinen, M. T.,
H. Hächler, and F. H. Kayser.
1995.
New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV -lactamases.
Antimicrob. Agents Chemother.
39:1726-1730[Abstract].
|
| 17. |
O'Callaghan, C. H.,
A. Morris,
S. M. Kirby, and A. H. Shingler.
1982.
Novel method for the detection of -lactamases by using a chromogenic cephalosporin substrate.
Antimicrob. Agents Chemother.
1:283-288.
|
| 18. |
Phillipon, A. M.,
G. C. Paul, and G. A. Jacoby.
1983.
Properties of PSE-2 -lactamase and genetic basis for its production in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
24:362-369 |
| 19. |
Podbielski, A.,
J. Schonling,
B. Melzer,
K. Warnatz, and H.-G. Leusch.
1991.
Molecular characterization of a new plasmid-encoded SHV-type -lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae.
J. Gen. Microbiol.
137:569-578 |
| 20. | Pridmore, R. D. 1987. New and versatile cloning vectors with kanamycin-resistance marker. Gene 56:309-312[Medline]. |
| 21. |
Verbist, L., and J. Verhaegen.
1980.
GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.
Antimicrob. Agents Chemother.
17:807-812 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»